aβ-in-1 tfa

Aβ-IN-1 TFA inhibits and reverses different types of protein aggregation.

Verubecestat TFA, also known as MK-8931 or SCH 900931, is a potent and selective beta-secretase inhibitor, and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor. Verubecestat TFA is a promising novel therapeutic drug candidate in Alzheimer's disease. Verubecestat TFA reduced Aβ cerebral spinal fluids (CSF) levels up to 92% and was well tolerated by patients.

LPYFD-NH2 TFA, a pentapeptide, inhibits Aβ(1-42) aggregation, indicating its potential utility in Alzheimer's disease research [1].

Amyloid β-Protein (3-42) TFA is a precursor of the Pyr peptide. The core of amyloid plaques in Alzheimer's disease is composed of pyroglutamate-modified Aβ (pEAβ) (3-42). Interestingly, pEAβ (3-42) accelerates the aggregation of Aβ(1-42), whereas Aβ(1-42) significantly slows both the primary and secondary nucleation of pEAβ(3-42).